[Urokinase as a blood and urine plasminogen activator in chronic glomerulonephritis and amyloidosis].
To estimate the individual role of the plasminogen activators (PA) urokinase (u-PA) and tissue (t-PA) in the development of two renal diseases (the nephrotic forms of chronic glomerulonephritis (CGN) and amyloidosis, the baseline plasma and urine levels of u-PA and t-PA antigens, their functional activity (FPAA), and changes in these parameters were determined after protein loading test (0.7 g/kg). In healthy individuals and patients with amyloidosis, the baseline FPAA changes from 0 to the maximum were caused only by the alterations of u-PA levels, in those with CGN, they were induced by the changes in the content of u-PA and t-AP antigens. The functional loading test revealed PA reserves solely in patients having a high baseline FPAA for both nephropathies: u-PA in amyloidosis and t-PA in CGN. In all the patients, the urine levels of u-PA antigens were 20-40 times more than those of t-PA antigens and 5-6 times less than those plasma u-PA. The findings suggest that urokinase may be regarded as the major plasminogen activator involved in CGN and amyloidosis.
Andreenko
G V
GV
Poliantseva
L R
LR
Podorol'skaia
L V
LV
Bumblite
I D
ID
D000686:Amyloidosis / Q000097:blood / Q000201:enzymology* / Q000652:urine; D015415:Biomarkers / Q000097:blood / Q000652:urine; D002908:Chronic Disease; D004797:Enzyme-Linked Immunosorbent Assay; D005500:Follow-Up Studies; D005921:Glomerulonephritis / Q000097:blood / Q000201:enzymology* / Q000652:urine; D006801:Humans; D010960:Plasminogen Activators / Q000378:metabolism*; D011379:Prognosis; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism*
D015415:Biomarkers; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator